Necrotising Enterocolitis Market Research Report – Forecast to 2027

Necrotising Enterocolitis (NEC) Market Research Report: By Stages (Stage I, Stage II, Stage III), Diagnosis (Imaging, Laboratory Studies), Treatment (TPN, Paracentesis, Antifungal) End-User (Hospital & Clinic, Diagnostic Center)– Global Forecast Till 2027

ID: MRFR/Pharma/4541-HCR | February 2021 | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


The global Necrotising Enterocolitis (NEC) market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the Necrotising Enterocolitis (NEC) market is expected to register a CAGR 5.5% during the forecast period of 2018 to 2023.


Necrotizing enterocolitis is the most common cause of gastrointestinal-related morbidity and mortality. The most premature infants are the most vulnerable. According to a study published in the Advances in Neonatal Care (2013), it was estimated that approximately 12% of infants born with the body weight of less than 1500 g are likely to develop Necrotizing Enterocolitis. The ascites condition is also found to be associated with Stage IIa and IIIa. The severity of the condition pushes the demand for better diagnosis and treatment approaches.  

Notably, the market is expected to expand in the near future due to the prevalence of necrotizing enterocolitis.


Various other factors such as improved reimbursement policies in developed countries, improving regulatory framework, growing research funding, unmet medical needs, and increasing government assistance are continuously contributing to the growth of the global Necrotising Enterocolitis (NEC) market. The increasing contribution of marketers is also fueling the growth of the market. For instance, on February 15, 2018, Prometic Life Sciences Inc. received the FDA orphan drug designation status to its Inter-Alpha-Inhibitor-Proteins ("IaIp") for the treatment of necrotizing enterocolitis.


Despite these drivers, there are some issues associated with the Necrotising Enterocolitis (NEC) market. The complications associated with the treatment, lack of skilled or trained physicians, and poor healthcare system in low and middle-income countries may hamper the growth of the market.


Intended Audience



  • Pharmaceutical Companies

  • Medical Devices Companies

  • Research and Development (R&D) Companies

  • Government Research Institutes

  • Academic Institutes and Universities


Regional Market Summary


The Americas dominates the Necrotising Enterocolitis (NEC) market owing to the increasing prevalence of chronic pain, well-developed technology, high healthcare expenditure, and the presence of leading players. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the U.S. region was reported to be USD 3.2 trillion hospital care accounted for a share of 32.3%.


Europe holds the second position in the Necrotising Enterocolitis (NEC) market. It is expected that the increasing contribution towards research and development and increasing competition among marketers are likely to drive the European Necrotising Enterocolitis (NEC) market.


Asia Pacific is the fastest growing Necrotising Enterocolitis (NEC) market owing to a huge patient pool, increasing demand for treatment, and rising healthcare expenditure. As per the data suggested by the Australian Institute of Health and Welfare during 2015 to 2016, the total health expenditure was nearly USD 170.4 billion, i.e., 3.6% higher than the expenditure of 2014 to 2015.


The Middle East and Africa holds the lowest share of the global Necrotising Enterocolitis (NEC) market due to low development, lack of technical knowledge, and poor medical facilities.


Key Players


Some of the key players in the global Necrotising Enterocolitis (NEC) market are Abbott Laboratories Inc. (U.S.), Astellas Pharma Inc. (Japan), Bayer HealthCare AG (Germany), Becton, Dickinson and Company (BD) (U.S.), Bristol-Myers Squibb Company (U.S.), Daiichi Sankyo Company , Ltd. (Japan), Eli Lilly and Co. (U.S.), Enzon Pharmaceuticals, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), GI Supply (U.S.), GlaxoSmithKline Plc (UK), Kyorin Pharmaceutical Co., Ltd. (U.S.), Medtronic Plc (U.S.), Merck & Co. Inc. (U.S.), MiddleBrook Pharmaceuticals (Japan), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Sanofi-Aventis (France), Sequana Medical AG (Switzerland), Takeda Pharmaceutical Company, Ltd. (Japan), and others.


Research Methodology


 Necrotising Enterocolitis


Sources: Annual reports, Press release, White paper, and Company presentation


Segmentation


The global Necrotising Enterocolitis (NEC) market is segmented on the basis of stage, diagnosis, treatment, and end-user.


Based on stage, the market is classified as Stage I, Stage II, and Stage III. The Stage II is further segmented into Stage IIa and Stage IIb. The Stage III is further segmented into Stage IIIa and Stage IIIb.


Based on diagnosis, the market is classified as imaging, laboratory studies, and differential diagnosis. The imaging segment is further classified as abdominal x-ray, Magnetic Resonance Imaging (MRI), ultrasound, laparoscopy, angiography, and others. The laboratory studies segment is further classified as haemochromocytometric exam, blood culture, serum electrolytes, arterial blood gas analysis, blood pressure monitor, and others. The differential diagnosis segment is further classified as ileus secondary to neonatal sepsis, spontaneous intestinal perforation, ileal atresia, intestinal malrotation, volvulus, neonatal appendicitis, neonatal pseudomembranous colitis, and others.


Based on treatment, the market is classified as Total Parenteral Nutrition (TPN), gastrointestinal decompression, antimicrobial therapy, antifungal treatment, paracentesis, and others.


Based on end-user, the market is classified as hospitals and clinics, ambulatory surgical center, diagnostic centers, and others.



TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Treatment Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Necrotising Enterocolitis (NEC) Market, by Stages

6.1 Introduction

6.2 Stage I

6.2.1 Market Estimates & Forecast, 2020–2027

6.3 Stage II

6.3.1 Stage IIa

6.3.2 Stage IIb

6.4 Stage III

6.4.1 Stage IIa

6.4.2 Stage IIb

Chapter 7. Global Necrotising Enterocolitis (NEC) Market, by Diagnosis

7.1 Introduction

7.2 Imaging

7.2.1 Abdominal X-Ray

7.2.2 Magnetic Resonance Imaging (MRI)

7.2.3 Ultrasound

7.2.4 Laparoscopy

7.2.5 Angiography

7.2.6 Others

7.3 Laboratory Studies

7.3.1 Haemochromocytometric Exam

7.3.2 Blood Culture

7.3.3 Serum Electrolytes

7.3.4 Arterial Blood Gas Analysis

7.3.5 Blood Pressure Monitor

7.4 Differential Diagnosis

7.4.1 Ileus Secondary to Neonatal Sepsis

7.4.2 Spontaneous Intestinal Perforation

7.4.3 Ileal Atresia

7.4.4 Intestinal Malrotation

7.4.5 Volvulus

7.4.6 Neonatal Appendicitis

7.4.7 Neonatal Pseudomembranous Colitis

7.4.8 Others

Chapter 8. Global Necrotising Enterocolitis (NEC) Market, by Treatment

8.1 Introduction

8.2 Total Parenteral Nutrition (TPN),

8.2.1 Market Estimates & Forecast, 2020–2027

8.3 Gastrointestinal Decompression

8.3.1 Market Estimates & Forecast, 2020–2027

8.4 Antimicrobial Therapy

8.4.1 Market Estimates & Forecast, 2020–2027

8.5 Antifungal Treatment

8.5.1 Market Estimates & Forecast, 2020–2027

8.6 Paracentesis

8.6.1 Market Estimates & Forecast, 2020–2027

8.7 Others

Chapter 9. Global Necrotising Enterocolitis (NEC) Market, by End-User

9.1 Introduction

9.2 Hospitals & Clinics

9.2.1 Market Estimates & Forecast, 2020–2027

9.3 Ambulatory Surgical Center

9.3.1 Market Estimates & Forecast, 2020–2027

9.4 Diagnostic Centers

9.4.1 Market Estimates & Forecast, 2020–2027

9.5 Others

9.5.1 Market Estimates & Forecast, 2020–2027

Chapter. 10 Global Necrotising Enterocolitis (NEC) Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 U.S.

10.2.1.1 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K.

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Rest of the Middle East & Africa

Chapter 11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

Chapter 12 Company Profiles

12.1 GlaxoSmithKline plc

12.1.1 Company Overview

12.1.2 Stages Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 F. Hoffmann-La Roche Ltd

12.2.1 Company Overview

12.2.2 Stages Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Pfizer Inc.

12.3.1 Company Overview

12.3.2 Stages Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Eli Lilly and Company

12.4.1 Company Overview

12.4.2 Stages/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Bayer HealthCare AG

12.5.1 Company Overview

12.5.2 Stages Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 Becton, Dickinson and Company

12.6.1 Company Overview

12.6.2 Stages Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 Bristol-Myers Squibb Company

12.7.1 Overview

12.7.2 Stages Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Medtronic Plc

12.8.1 Company Overview

12.8.2 Stages/Business Segment Overview

12.8.3 Financial Overview

12.8.4 Key Development

12.8.5 SWOT Analysis

12.9 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of the Pharmaceutical industry

Chapter 14 Appendix

LIST OF TABLES

Table 1 Necrotising Enterocolitis (NEC) Industry Synopsis, 2020–2027

Table 2 Necrotising Enterocolitis (NEC) Market Estimates and Forecast, 2020–2027, (USD Million)

Table 3 Necrotising Enterocolitis (NEC) Market, by Region, 2020–2027, (USD Million)

Table 4 Necrotising Enterocolitis (NEC) Market, by Stages, 2020–2027, (USD Million)

Table 5 Necrotising Enterocolitis (NEC) Market, by Diagnosis, 2020–2027, (USD Million)

Table 6 Necrotising Enterocolitis (NEC) Market, by Treatment, 2020–2027, (USD Million)

Table 7 Necrotising Enterocolitis (NEC) Market, by End-User, 2020–2027, (USD Million)

Table 8 North America Necrotising Enterocolitis (NEC) Market, by Stages, 2020–2027, (USD Million)

Table 9 North America Necrotising Enterocolitis (NEC) Market, by Diagnosis, 2020–2027, (USD Million)

Table 10 North America Necrotising Enterocolitis (NEC) Market, by Treatment, 2020–2027, (USD Million)

Table 11 North America Necrotising Enterocolitis (NEC) Market, by End-User, 2020–2027, (USD Million)

Table 12 U.S. Necrotising Enterocolitis (NEC) Market, by Stages, 2020–2027, (USD Million)

Table 13 U.S. Necrotising Enterocolitis (NEC) Market, by Diagnosis, 2020–2027, (USD Million)

Table 14 U.S. Necrotising Enterocolitis (NEC) Market, by Treatment, 2020–2027, (USD Million)

Table 15 U.S. Necrotising Enterocolitis (NEC) Market, by End-User, 2020–2027, (USD Million)

Table 16 Canada Necrotising Enterocolitis (NEC) Market, by Stages, 2020–2027, (USD Million)

Table 17 Canada Necrotising Enterocolitis (NEC) Market, by Diagnosis, 2020–2027, (USD Million)

Table 18 Canada Necrotising Enterocolitis (NEC) Market, by Treatment, 2020–2027, (USD Million)

Table 19 Canada Necrotising Enterocolitis (NEC) Market, by End-User, 2020–2027, (USD Million)

Table 20 South America Necrotising Enterocolitis (NEC) Market, by Stages, 2020–2027, (USD Million)

Table 21 South America Necrotising Enterocolitis (NEC) Market, by Diagnosis, 2020–2027, (USD Million)

Table 22 South America Necrotising Enterocolitis (NEC) Market, by Treatment, 2020–2027, (USD Million)

Table 23 South America Necrotising Enterocolitis (NEC) Market, by End-User, 2020–2027, (USD Million)

Table 24 Europe Necrotising Enterocolitis (NEC) Market, by Stages, 2020–2027, (USD Million)

Table 25 Europe Necrotising Enterocolitis (NEC) Market, by Diagnosis, 2020–2027, (USD Million)

Table 26 Europe Necrotising Enterocolitis (NEC) Market, by Treatment, 2020–2027, (USD Million)

Table 27 Europe Necrotising Enterocolitis (NEC) Market, by End-User, 2020–2027, (USD Million)

Table 28 Western Europe Necrotising Enterocolitis (NEC) Market, by Stages, 2020–2027, (USD Million)

Table 29 Western Europe Necrotising Enterocolitis (NEC) Market, by Diagnosis, 2020–2027, (USD Million)

Table 30 Western Europe Necrotising Enterocolitis (NEC) Market, by Treatment, 2020–2027, (USD Million)

Table 31 Western Europe Necrotising Enterocolitis (NEC) Market, by End-User, 2020–2027, (USD Million)

Table 32 Eastern Europe Necrotising Enterocolitis (NEC) Market, by Stages, 2020–2027, (USD Million)

Table 33 Eastern Europe Necrotising Enterocolitis (NEC) Market, by Diagnosis, 2020–2027, (USD Million)

Table 34 Eastern Europe Necrotising Enterocolitis (NEC) Market, by Treatment, 2020–2027, (USD Million)

Table 35 Eastern Europe Necrotising Enterocolitis (NEC) Market, by End-User, 2020–2027, (USD Million)

Table 36 Asia Pacific Necrotising Enterocolitis (NEC) Market, by Stages, 2020–2027, (USD Million)

Table 37 Asia Pacific Necrotising Enterocolitis (NEC) Market, by Diagnosis, 2020–2027, (USD Million)

Table 38 Asia Pacific Necrotising Enterocolitis (NEC) Market, by Treatment, 2020–2027, (USD Million)

Table 39 Asia Pacific Necrotising Enterocolitis (NEC) Market, by End-User, 2020–2027, (USD Million)

Table 40 The Middle East & Africa Necrotising Enterocolitis (NEC) Market, by Stages, 2020–2027, (USD Million)

Table 41 The Middle East & Africa Necrotising Enterocolitis (NEC) Market, by Diagnosis, 2020–2027, (USD Million)

Table 42 The Middle East & Africa Necrotising Enterocolitis (NEC) Market, by Treatment, 2020–2027, (USD Million)

Table 43 The Middle East & Africa Necrotising Enterocolitis (NEC) Market, by End-User, 2020–2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Necrotising Enterocolitis (NEC) Market

Figure 3 Segmentation Market Dynamics for Necrotising Enterocolitis (NEC) Market

Figure 4 Global Necrotising Enterocolitis (NEC) Market Share, by Stages 2020

Figure 5 Global Necrotising Enterocolitis (NEC) Market Share, by Diagnosis 2020

Figure 6 Global Necrotising Enterocolitis (NEC) Market Share, by Treatment, 2020

Figure 7 Global Necrotising Enterocolitis (NEC) Market Share, by End-User, 2020

Figure 9 Global Necrotising Enterocolitis (NEC) Market Share, by Region, 2020

Figure 10 North America Necrotising Enterocolitis (NEC) Market Share, by Country, 2020

Figure 11 Europe Necrotising Enterocolitis (NEC) Market Share, by Country, 2020

Figure 12 Asia Pacific Necrotising Enterocolitis (NEC) Market Share, by Country, 2020

Figure 13 The Middle East & Africa Necrotising Enterocolitis (NEC) Market Share, by Country, 2020

Figure 14 Global Necrotising Enterocolitis (NEC) Market: Company Share Analysis, 2020 (%)

Figure 15 GlaxoSmithKline plc: Key Financials

Figure 16 GlaxoSmithKline plc: Segmental Revenue

Figure 17 GlaxoSmithKline plc: Geographical Revenue

Figure 18 F. Hoffmann-La Roche Ltd: Key Financials

Figure 19 F. Hoffmann-La Roche Ltd: Segmental Revenue

Figure 20 F. Hoffmann-La Roche Ltd: Geographical Revenue

Figure 21 Pfizer Inc.: Key Financials

Figure 22 Pfizer Inc.: Segmental Revenue

Figure 23 Pfizer Inc.: Geographical Revenue

Figure 24 Eli Lilly and Company: Key Financials

Figure 25 Eli Lilly and Company: Segmental Revenue

Figure 26 Eli Lilly and Company: Geographical Revenue

Figure 27 Bayer HealthCare AG.: Key Financials

Figure 28 Bayer HealthCare AG.: Segmental Revenue

Figure 29 Bayer HealthCare AG.: Geographical Revenue

Figure 30 Becton, Dickinson and Company: Key Financials

Figure 31 Becton, Dickinson and Company: Segmental Revenue

Figure 32 Becton, Dickinson and Company: Geographical Revenue

Figure 33 Bristol-Myers Squibb Company: Key Financials

Figure 34 Bristol-Myers Squibb Company: Segmental Revenue

Figure 35 Bristol-Myers Squibb Company: Geographical Revenue

Figure 36 Medtronic Plc: Key Financials

Figure 37 Medtronic Plc: Segmental Revenue

Figure 39 Medtronic Plc: Geographical Revenue